PGC-1α Agonist Rescues Doxorubicin-Induced Cardiomyopathy by Mitigating the Oxidative Stress and Necroptosis

Area of Science:

• Cardiovascular Research
• Mitochondrial Biology
• Pharmacology

Background:

• Cardiomyopathy, particularly dilated cardiomyopathy (DCM), is a major cause of heart failure (HF).
• Doxorubicin (DOX)-induced cardiotoxicity presents morphological and functional cardiac defects similar to DCM.
• Inflammatory factors exacerbate HF symptoms, highlighting the need for effective therapeutic targets.

Purpose of the Study:

• To investigate the therapeutic potential of a PGC-1α agonist (ZLN005) in mitigating doxorubicin-induced cardiomyopathy (DIC) in mice.
• To evaluate the effects of PGC-1α activation on cardiac fibrosis, oxidative stress, and necroptosis markers in a mouse model of DIC.

Main Methods:

• Forty male C57BL/6J mice were divided into four groups: Control, DOX, ZLN005, and ZLN005 + DOX.
• DOX was administered at a single dose of 10 mg/kg to induce cardiomyopathy.
• ZLN005 (a PGC-1α agonist) was administered at 2.5 mg/kg/dose for four doses.
• Cardiac fibrosis was assessed using Masson Trichrome/Picrosirius red staining and α-Smooth Muscle Actinin (α-SMA) expression.
• Oxidative stress and necroptosis markers were evaluated in cardiac tissues.

Main Results:

• DOX administration induced a DCM-like phenotype with significant cardiac fibrosis and functional impairment.
• Treatment with the PGC-1α agonist ZLN005 attenuated DOX-induced cardiac fibrosis, as evidenced by reduced Masson Trichrome/Picrosirius red staining and α-SMA expression.
• The PGC-1α agonist alleviated elevated expression of necroptosis markers and reduced oxidative stress in DOX-treated mice.

Conclusions:

• PGC-1α activation, via the agonist ZLN005, demonstrates potent therapeutic efficacy in mitigating the deleterious effects of doxorubicin-induced cardiomyopathy.
• This study suggests that targeting PGC-1α may represent a promising therapeutic strategy for managing doxorubicin cardiotoxicity and potentially dilated cardiomyopathy/heart failure.